回盛生物
(300871)
| 流通市值：41.32亿 | | | 总市值：41.32亿 |
| 流通股本：1.84亿 | | | 总股本：1.84亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 399,068,578.25 | 1,200,327,933.81 | 792,553,431.27 | 436,303,723.6 |
| 营业收入 | 399,068,578.25 | 1,200,327,933.81 | 792,553,431.27 | 436,303,723.6 |
| 二、营业总成本 | 358,778,707.57 | 1,229,801,069.41 | 838,141,263.93 | 468,045,931.31 |
| 营业成本 | 301,383,750.13 | 1,004,267,693.89 | 662,167,979.36 | 353,277,702.42 |
| 税金及附加 | 2,579,728.94 | 10,508,494.04 | 7,340,513.41 | 4,641,663.07 |
| 销售费用 | 17,052,315.63 | 59,253,062.89 | 44,509,417.85 | 29,001,399.62 |
| 管理费用 | 14,904,871.45 | 59,484,458.7 | 52,357,035.94 | 34,982,278.61 |
| 研发费用 | 14,377,751.93 | 55,797,216.51 | 38,952,745.03 | 26,461,413.27 |
| 财务费用 | 8,480,289.49 | 40,490,143.38 | 32,813,572.34 | 19,681,474.32 |
| 其中:利息费用 | 9,162,902.53 | 42,664,265.18 | 34,195,217.14 | 21,516,123.43 |
| 其中:利息收入 | 660,018.52 | 1,839,973.64 | 1,458,036.27 | 1,121,276.81 |
| 加:公允价值变动收益 | 8,711,382.63 | -23,638,504.81 | -37,453,462.24 | -49,002,063.88 |
| 加:投资收益 | 654,816.22 | 8,185,502.6 | 7,430,344.39 | 5,747,399.98 |
| 资产减值损失(新) | -751,649.79 | -1,340,697.97 | -1,582,610.81 | -3,096,367.8 |
| 信用减值损失(新) | -3,220,185.13 | 680,278.53 | 3,939,216.38 | 5,963,681.72 |
| 其他收益 | 5,184,773.97 | 16,501,434.1 | 12,119,476.6 | 7,495,427.4 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 50,869,008.58 | -29,085,123.15 | -61,134,868.34 | -64,634,130.29 |
| 加:营业外收入 | 94,067.7 | 390,029.8 | 77,279.57 | 59,723.92 |
| 减:营业外支出 | 281,877.52 | 278,326.13 | 146,031.82 | 111,694.82 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 50,681,198.76 | -28,973,419.48 | -61,203,620.59 | -64,686,101.19 |
| 减:所得税费用 | 5,903,701.64 | -9,200,254.6 | -13,587,630.42 | -12,807,044 |
| 六、净利润 | 44,777,497.12 | -19,773,164.88 | -47,615,990.17 | -51,879,057.19 |
| 持续经营净利润 | 44,777,497.12 | -19,773,164.88 | -47,615,990.17 | -51,879,057.19 |
| 归属于母公司股东的净利润 | 44,496,959.41 | -20,155,591.43 | -47,658,306.03 | -51,878,681.23 |
| 少数股东损益 | 280,537.71 | 382,426.55 | 42,315.86 | -375.96 |
| (一)基本每股收益 | 0.27 | -0.12 | -0.29 | -0.31 |
| (二)稀释每股收益 | 0.25 | -0.12 | -0.29 | -0.31 |
| 八、其他综合收益 | - | - | -767,307.88 | -1,587,603.84 |
| 归属于母公司股东的其他综合收益 | - | - | -767,307.88 | -1,587,603.84 |
| 九、综合收益总额 | 44,777,497.12 | -19,773,164.88 | -48,383,298.05 | -53,466,661.03 |
| 归属于母公司股东的综合收益总额 | 44,496,959.41 | -20,155,591.43 | -48,425,613.91 | -53,466,285.07 |
| 归属于少数股东的综合收益总额 | 280,537.71 | 382,426.55 | 42,315.86 | -375.96 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-30 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |